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OBJECTIVE: To analyse the cost-minimization of Everolimus
in comparison with Sirolimus for immunosuppression in kidney
transplantation. METHODS: A cost-minimization analysis from
the Brazilian National Health system perspective, with a time
horizon of seven years were conducted. A decision tree with a
Markov chain considering the probabilities of graft loss or main-
tenance through health states related to presence or absence of
any relevant health event, were performed. Study comparators
examined were Everolimus (EVE) and Sirolimus (SLR). The clini-
cal aspects regarding beneﬁts and probabilities of transition data
were extract from meta-analysis of published randomized clinical
trials for the alternatives. The analysis is based on Brazilian
current clinical practice. Treatment costs were collected from
public reimbursement list. Costs and beneﬁts were validated by
a panel of Brazilian specialists from Ministry of Health through
the Delphi technique. The discounting rate was 5% for costs
and beneﬁts, the results were converted in US Dollars (R$1.8/
USD$1.00). A one-way sensitivity analysis was performed.
RESULTS: Patients using Everolimus get the lowest total cost per
treatment (EVE = $15,347.58USD; SLR = $29,959.6USD). The
sensitivity analysis on costs variables in an interval of 80%,
was robust with the base analysis. CONCLUSION: Everolimus
is a cost-saving alternative for immunossuppresion in kidney
transplantation compared to Sirolimus in the perspective of
Brazilian Public Health System.
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OBJECTIVE: Current National Institute for Health and Clinical
Excellence (NICE) Clinical Guidelines on managing anemia in
patients with chronic kidney disease (CKD) state that there is
no evidence to differentiate between erythropoiesis-stimulating
agents in terms of efﬁcacy. Cost minimization analysis (CMA) is,
therefore, an appropriate health economic approach in this
therapy area. This CMA of epoetin zeta (Retacrit®), a biosimilar
agent of epoetin alfa, versus current standard treatments was
conducted from the perspective of NHS Scotland. METHODS: A
CMA of intravenous and subcutaneous epoetin, published in the
full NICE Clinical Guidelines, was used as a framework for this
cost analysis of epoetin zeta, the reference product epoetin alfa,
epoetin beta and darbepoetin alfa. In both the NICE and this
analysis, it was assumed that the cost difference of epoetin and
iron administration would be negligible. Licensed epoetin doses
were incorporated in this analysis. RESULTS: This analysis dem-
onstrates that epoetin zeta minimizes costs for treating anemia
associated with CKD when compared with the reference product,
epoetin alfa. The cost of epoetin zeta for a hemodialysis patient
is £59.39/week (hemoglobin correction phase) and £29.70–
£118.79/week (hemoglobinmaintenance phase), based on a 70 kg
patient. The corresponding cost for a patient treated with epoetin
alfa is £67.32/week and £33.66–£134.64/week. The low drug
acquisition cost for epoetin zeta could lead to potential cost
savings. CONCLUSION: CMA is an appropriate approach for
managing anemia in peoplewithCKD.This analysis demonstrates
that the biosimilar product, epoetin zeta, minimizes treatment
costs and would be of beneﬁt to patients and NHS Scotland.
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OBJECTIVE: Using data from a large, multicenter, double-blind,
phase III clinical trial designed to evaluate the efﬁcacy and safety
of a vaccine intended to reduce the incidence of S. aureus infec-
tion in adults with ESRD receiving hemodialysis, we examined
inpatient costs, inpatient days, and mortality associated with
S. aureus bloodstream and non-bloodstream infections.
METHODS: Inpatient bills were obtained for patients hospital-
ized with S. aureus infection. Clinical and laboratory data were
recorded in the report form. Hospital charges were converted to
costs using department-level cost-to-charge ratios derived from
each hospital’s Annual Medicare Cost Report. Statistics were
used to report 12-week economic and clinical outcomes. Among
patients with S. aureus bacteremia, those with additional sites of
S. aureus infection were compared to those without using gener-
alized linear regression models adjusting for confounders.
RESULTS: Among 89 patients hospitalized with S. aureus bac-
teremia, the mean inpatient cost was $19,454 (median: $13,011)
over 12 weeks, representing an average of 11.9 inpatient days.
Among 70 patients hospitalized with non-bloodstream S. aureus
infections, the mean 12-week cost was $19,222 (median:
$13,106) across a mean of 11.3 inpatient days. Twelve-week
mortality was 20.2% for patients with S. aureus bacteremia and
15.7% for patients with non-bloodstream S.aureus infections.
When adjusting for baseline demographics and medical history
among patients with S. aureus bacteremia, those who experi-
enced additional sites of S. aureus infection (n = 33) incurred
1.43-fold higher 12-week inpatients costs compared to those
without sites of S. aureus infection (p = 0.0497). Inpatient days
(13.5 vs. 11.0; P = 0.3154) and 12-week mortality (15.15% vs.
23.21%; P = 0.6569) did not signiﬁcantly differ between S.
aureus bacteremia patients with and without additional sites of
S. aureus infection. CONCLUSION: S. aureus infections impose
considerable economic burden in ESRD patients undergoing
hemodialysis. The existence of additional sites of S. aureus
infection among patients with S. aureus bacteremia increases
inpatient costs.
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OBJECTIVE: Angiogenesis inhibitor therapies (oral sunitinib or
sorafenib, or IV bevacizumab off-label) are currently available as
treatments for RCC patients. However, IV therapy may impose
additional burdens for patients such as time lost in travel to
treatment facilities, infection risk from IV catheters and increased
costs. The potential incremental cost by resource use category
associated with IV vs. oral administration of selected angiogen-
esis inhibitor therapies for the treatment of RCC was evaluated.
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